{"id":793857,"date":"2024-12-10T10:23:07","date_gmt":"2024-12-10T15:23:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/"},"modified":"2024-12-10T10:23:07","modified_gmt":"2024-12-10T15:23:07","slug":"glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/","title":{"rendered":"Glass Lewis Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan, Thomas K. Equelsand Dr. William M. Mitchell"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Glass Lewis Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan, Thomas K. Equels<\/b><b>and Dr. William M. Mitchell<\/b><\/p>\n<p class=\"bwalignc\"><i>Both Leading Independent Proxy Advisory Firms \u2013 ISS and Glass Lewis \u2013 Conclude That Activist Group\u2019s Plan Lacks Detail and Does Not Justify Control of the Board<\/i><\/p>\n<p class=\"bwalignc\"><i>ISS and Glass Lewis Both Recommend Against the Election of Activist Group Nominees Todd A. Deutsch and Robert L. Chioini, with Glass Lewis Also Recommending Against the Election of Paul W. Sweeney<\/i><\/p>\n<p class=\"bwalignc\"><i>Company Urges Shareholders to Safeguard AIM by Voting \u201cFOR\u201d ALL Four of the Board\u2019s Incumbent Candidates on the <b><span class=\"bwuline\">WHITE<\/span><\/b> Universal Proxy Card and Discarding Any Proxy Materials Received from the Activist Group<\/i><\/p>\n<p>OCALA, Fla.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAIM ImmunoTech Inc. (NYSE American: AIM) (\u201cAIM\u201d or the \u201cCompany\u201d) today announced that independent proxy advisory firm Glass, Lewis &amp; Co., LLC (\u201cGlass Lewis\u201d) has recommended that shareholders vote \u201cFOR\u201d Company nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell at the upcoming 2024 Annual Meeting of Stockholders (the \u201cAnnual Meeting\u201d), presently scheduled for December 17, 2024.<\/p>\n<p>\nIn reaching its recommendation against giving the activist investors\u2019 (the \u201cActivist Group\u201d) nominees control of the AIM Board of Directors (the \u201cBoard\u201d), Glass Lewis noted the following: <sup>1<\/sup><\/p>\n<ul class=\"bwlistdisc\">\n<li><b><i>\u201c\u2026the [Activist Group\u2019s] presented plan lacks substantive detail. For instance, it does not provide for a particular clinical strategy and relies on a full review of Ampligen&#8217;s indications to define such strategy, lacks a clear view on the Company&#8217;s management going forward, and does not indicate the less dilutive and less expensive financing options that may be available to the Company.\u201d<\/i><\/b><\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b><i>\u201c\u2026 we do not believe the Dissident Group presented a fully qualified board slate of candidates to justify shareholder support of all four nominees.\u201d<\/i><\/b><\/li>\n<\/ul>\n<p>\nGlass Lewis also pointed out Activist Group nominee Robert L. Chioini\u2019s poor track record:<\/p>\n<ul class=\"bwlistdisc\">\n<li><b><i>\u201cWe believe the board raised valid concerns regarding Mr. Chioini\u2019s record at Rockwell Medical, including failing to execute the go-to-market strategy for its product.<\/i><\/b><b><i>As discussed in our proxy paper for Rockwell Medical\u2019s meeting held on June 01, 2017 (i.e., approximately one year prior to Mr. Chioini&#8217;s termination), the entity under his leadership has failed to deliver on promises of a strong sales stream, despite the multi-year presence of two marketable products, and was underperforming relative to its peers in terms of TSRs.\u201d<\/i><\/b><\/li>\n<\/ul>\n<p>\nDr. William M. Mitchell, Chairman of the Board, stated:<\/p>\n<p><i>\u201cWe appreciate Glass Lewis\u2019s support for the election of three of our nominees, Nancy K. Bryan, Thomas K. Equels and myself. Two leading independent proxy advisory firms have now recommended against giving the Activist Group control of AIM\u2019s Board, citing the clear lack of detail in their plan for AIM and concerns with the backgrounds of their nominees. While we are grateful for this support, we disagree with Glass Lewis\u2019s conclusion regarding AIM director Stewart Appelrouth. We firmly believe Mr. Appelrouth brings financial and regulatory expertise that is critical to AIM\u2019s success as we work to position the Company for upcoming clinical milestones. We encourage investors to vote for all four of our directors and help us maintain our momentum to deliver value for patients and shareholders.\u201d<\/i><\/p>\n<p>\nAIM encourages shareholders to vote \u201c<b>FOR<\/b>\u201d ALL four of the Board\u2019s incumbent candidates \u2013 <b>Stewart L. Appelrouth<\/b>, <b>Nancy K. Bryan<\/b>, <b>Thomas K. Equels<\/b> and <b>Dr. William M. Mitchell<\/b> \u2013 in connection with the Annual Meeting, on the <b><span class=\"bwuline\">WHITE<\/span><\/b> universal proxy card.<\/p>\n<p>\nFor more information on how to vote, visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.SafeguardAIM.com&amp;esheet=54164619&amp;newsitemid=20241210922287&amp;lan=en-US&amp;anchor=www.SafeguardAIM.com&amp;index=1&amp;md5=9a77ee98d955472cc5c3922baef33bbd\">www.SafeguardAIM.com<\/a>.<\/p>\n<p class=\"bwalignc\">\n***<\/p>\n<p><b>About AIM ImmunoTech Inc.<\/b><\/p>\n<p>\nAIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company\u2019s lead product is a first-in-class investigational drug called Ampligen<sup>\u00ae<\/sup> (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.<\/p>\n<p>\nFor more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DNJE1OVmM3vXX32UkYGXxM6a6gkfQ_2DnYLGx5Klimcg0SIUEXl6aHRMSXtvH1CLTDWpH3rTZCiAufpi5t6p-9p0EjO4NkMNsbEmaTpDEswzNvszJH-aM8EOVRVV888nSbRAC2vgyABZdN43GQxbKWBWzq50NJCOKM_txPvOidUGSpZiA6wkCZ9XafYPMf374-f3xMdS5d6mvfaEOh-SJLIKjWpDnDC4MU6UbdbumhiM%3D&amp;esheet=54164619&amp;newsitemid=20241210922287&amp;lan=en-US&amp;anchor=aimimmuno.com&amp;index=2&amp;md5=04cf0a2da3322694ca38d212e0c09c79\">aimimmuno.com<\/a> and connect with the Company on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D92BdXKffHdlioqhz-03Fs1SCxSuJ_YoMC7zzeRUzUmKpf7AaDkBpYBTNmSb7rglz-sAOfhSiDQnjcDs7oVHDxRh8XwYe4c-pmYVskUuuh8bvCHDBFGX4xLNz1zK4hU7V6GLIwLCNHTpTc3UrFO1v2vYwW81LULNmHnyAioz-3x4z48aJsAJoIQ8tFBHNuatL8y9ibmHX8n4XrDgC1-b7mA%3D%3D&amp;esheet=54164619&amp;newsitemid=20241210922287&amp;lan=en-US&amp;anchor=X&amp;index=3&amp;md5=6130a9fb6e60dbde487478642b59c6ae\">X<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DsH78EHx_UKrXcfI2LUu9Z-lJSSOS6QZWbFZ_oXe2paNrGUii0hZrZS-O8LpzT9xas82flUWriJU1CELIbJRK3auVrVaEDkTliYmOtiiS1roLBVcUKuFc-VDV3F9CDOzZtpr5OP-EhbFK6rWaduz5-fjevnRRIXmlvFUqnlpPBQjjsV2btrpz-PCrlg5pZboGQ-kTvRf26jHEl590OiKDSQJFO18V8Jv64H91CHtkRYqC2k-setqZttauwo7FW8mY&amp;esheet=54164619&amp;newsitemid=20241210922287&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=b4daa58f6f761c31a1872dd0b518dba7\">LinkedIn<\/a>, and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DJeXN46_2i1JvodZ_6kBxk9GunKEzpFGqa2Zmmrlzfr4Raz091cyw-p8SHz23j3lH6K5xQJYu-rKrBzzt7EpdtatCcPFQhMr5aS_RpmlQP2HbCicT2yIIM0Ye7C_X2GrDyMo2HtaxnWuXkNHO4tixq669IbfdjHIGzxPmlgv2n2HYlb4VgXnlnYvcMdFgr2LS-P21zmT51kPJv3oeCw7PI4dx2Oaf5iH_8SeuZPb3MuZi95OBx6XpmsSUQjgSPirK&amp;esheet=54164619&amp;newsitemid=20241210922287&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=9bcee5e726c4de9a0e99c9cdb18036b0\">Facebook<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the \u201cPSLRA\u201d). Words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccontinue,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d \u201cupcoming\u201d and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date does not guarantee that Ampligen will be approved as a treatment or therapy for any diseases or conditions. The Company urges investors to consider specifically the various risk factors identified in its most recent Annual Report on Form 10-K, and any risk factors or cautionary statements included in any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K, filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.<\/p>\n<p><b>Important Additional Information<\/b><\/p>\n<p>\nThe Company, its directors and executive officers, Peter W. Rodino, III and Robert Dickey, IV, are deemed to be \u201cparticipants\u201d (as defined in Section 14(a) of the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from the Company\u2019s stockholders in connection with the Annual Meeting. The Company filed its definitive proxy statement (the \u201cDefinitive Proxy Statement\u201d) and a <b>WHITE <\/b>universal proxy card with the SEC on November 4, 2024 in connection with such solicitation of proxies from the Company\u2019s stockholders. <b>STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH DEFINITIVE PROXY STATEMENT, ACCOMPANYING WHITE UNIVERSAL PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING.<\/b> The Definitive Proxy Statement contains information regarding the identity of the participants, and their direct and indirect interests, by security holdings or otherwise, in the Company\u2019s securities and can be found in the section titled \u201cPrincipal Stockholders\u201d of the Definitive Proxy Statement and available <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sec.gov%2FArchives%2Fedgar%2Fdata%2F946644%2F000149315224043423%2Fformdefc14a.htm%23%3A%7E%3Atext%3Dour%2520common%2520stock.-%2CPRINCIPAL%2520STOCKHOLDERS%2C-The%2520following%2520table&amp;esheet=54164619&amp;newsitemid=20241210922287&amp;lan=en-US&amp;anchor=here&amp;index=6&amp;md5=9c17ce29d9d21dbe6a6767bdf18915e0\">here<\/a>. Information regarding subsequent changes to their holdings of the Company\u2019s securities can be found in the SEC filings on Forms 3, 4, and 5, which are available on the Company\u2019s website available <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Faimimmuno.com%2Fsec-filings%2F&amp;esheet=54164619&amp;newsitemid=20241210922287&amp;lan=en-US&amp;anchor=here&amp;index=7&amp;md5=487ed3582e56216d8144692722e376c6\">here<\/a> or through the SEC\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=54164619&amp;newsitemid=20241210922287&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=94fca1c90e78281ac98e34f7d7d18609\">www.sec.gov<\/a>. Stockholders will be able to obtain the Definitive Proxy Statement, any amendments or supplements thereto and other documents filed by the Company with the SEC at no charge at the SEC\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=54164619&amp;newsitemid=20241210922287&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=9a6e3e01696501e5ab7197dc6de9ac7c\">www.sec.gov<\/a>. Copies will also be available at no charge at the Company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Faimimmuno.com%2Fsec-filings%2F&amp;esheet=54164619&amp;newsitemid=20241210922287&amp;lan=en-US&amp;anchor=https%3A%2F%2Faimimmuno.com%2Fsec-filings%2F&amp;index=10&amp;md5=15556e96826a625f93961decc01d3683\">https:\/\/aimimmuno.com\/sec-filings\/<\/a>.<\/p>\n<p><sup>____________________<br \/>\n<br \/>1<\/sup> Permission to quote Glass Lewis was neither sought nor obtained. Emphasis added.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241210922287r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20241210922287\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20241210922287\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><\/p>\n<p>JTC Team, LLC<br \/>\n<br \/>Jenene Thomas<br \/>\n<br \/>908-824-0775<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:AIM@jtcir.com\">AIM@jtcir.com<br \/>\n<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><\/p>\n<p>Longacre Square Partners<br \/>\n<br \/>Joe Germani \/ Miller Winston<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:AIM@longacresquare.com\">AIM@longacresquare.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Florida United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Infectious Diseases General Health Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Glass Lewis Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan, Thomas K. Equelsand Dr. William M. Mitchell Both Leading Independent Proxy Advisory Firms \u2013 ISS and Glass Lewis \u2013 Conclude That Activist Group\u2019s Plan Lacks Detail and Does Not Justify Control of the Board ISS and Glass Lewis Both Recommend Against the Election of Activist Group Nominees Todd A. Deutsch and Robert L. Chioini, with Glass Lewis Also Recommending Against the Election of Paul W. Sweeney Company Urges Shareholders to Safeguard AIM by Voting \u201cFOR\u201d ALL Four of the Board\u2019s Incumbent Candidates on the WHITE Universal Proxy Card and Discarding Any Proxy Materials Received from the Activist Group OCALA, Fla.&#8211;(BUSINESS WIRE)&#8211; AIM ImmunoTech Inc. (NYSE American: AIM) &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Glass Lewis Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan, Thomas K. Equelsand Dr. William M. Mitchell&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-793857","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Glass Lewis Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan, Thomas K. Equelsand Dr. William M. Mitchell - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Glass Lewis Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan, Thomas K. Equelsand Dr. William M. Mitchell - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Glass Lewis Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan, Thomas K. Equelsand Dr. William M. Mitchell Both Leading Independent Proxy Advisory Firms \u2013 ISS and Glass Lewis \u2013 Conclude That Activist Group\u2019s Plan Lacks Detail and Does Not Justify Control of the Board ISS and Glass Lewis Both Recommend Against the Election of Activist Group Nominees Todd A. Deutsch and Robert L. Chioini, with Glass Lewis Also Recommending Against the Election of Paul W. Sweeney Company Urges Shareholders to Safeguard AIM by Voting \u201cFOR\u201d ALL Four of the Board\u2019s Incumbent Candidates on the WHITE Universal Proxy Card and Discarding Any Proxy Materials Received from the Activist Group OCALA, Fla.&#8211;(BUSINESS WIRE)&#8211; AIM ImmunoTech Inc. (NYSE American: AIM) &hellip; Continue reading &quot;Glass Lewis Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan, Thomas K. Equelsand Dr. William M. Mitchell&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-10T15:23:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241210922287r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Glass Lewis Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan, Thomas K. Equelsand Dr. William M. Mitchell\",\"datePublished\":\"2024-12-10T15:23:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\\\/\"},\"wordCount\":1233,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241210922287r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\\\/\",\"name\":\"Glass Lewis Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan, Thomas K. Equelsand Dr. William M. Mitchell - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241210922287r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2024-12-10T15:23:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241210922287r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241210922287r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glass Lewis Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan, Thomas K. Equelsand Dr. William M. Mitchell\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Glass Lewis Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan, Thomas K. Equelsand Dr. William M. Mitchell - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/","og_locale":"en_US","og_type":"article","og_title":"Glass Lewis Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan, Thomas K. Equelsand Dr. William M. Mitchell - Market Newsdesk","og_description":"Glass Lewis Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan, Thomas K. Equelsand Dr. William M. Mitchell Both Leading Independent Proxy Advisory Firms \u2013 ISS and Glass Lewis \u2013 Conclude That Activist Group\u2019s Plan Lacks Detail and Does Not Justify Control of the Board ISS and Glass Lewis Both Recommend Against the Election of Activist Group Nominees Todd A. Deutsch and Robert L. Chioini, with Glass Lewis Also Recommending Against the Election of Paul W. Sweeney Company Urges Shareholders to Safeguard AIM by Voting \u201cFOR\u201d ALL Four of the Board\u2019s Incumbent Candidates on the WHITE Universal Proxy Card and Discarding Any Proxy Materials Received from the Activist Group OCALA, Fla.&#8211;(BUSINESS WIRE)&#8211; AIM ImmunoTech Inc. (NYSE American: AIM) &hellip; Continue reading \"Glass Lewis Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan, Thomas K. Equelsand Dr. William M. Mitchell\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-10T15:23:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241210922287r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Glass Lewis Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan, Thomas K. Equelsand Dr. William M. Mitchell","datePublished":"2024-12-10T15:23:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/"},"wordCount":1233,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241210922287r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/","name":"Glass Lewis Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan, Thomas K. Equelsand Dr. William M. Mitchell - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241210922287r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2024-12-10T15:23:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241210922287r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241210922287r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glass-lewis-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-thomas-k-equelsand-dr-william-m-mitchell\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Glass Lewis Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan, Thomas K. Equelsand Dr. William M. Mitchell"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/793857","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=793857"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/793857\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=793857"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=793857"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=793857"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}